Core Viewpoint - The stock of HAPO Pharmaceutical-B (02142) has seen an increase of nearly 4%, currently trading at 13.76 HKD, following the announcement of an enhanced global strategic collaboration with AstraZeneca, focusing on the development of next-generation biotherapies including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] Group 1: Strategic Collaboration - HAPO Pharmaceutical has announced an update to its global strategic collaboration with AstraZeneca established in March 2025 [1] - The collaboration will leverage both companies' expertise to jointly discover and develop new biotherapies [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership [1] Group 2: Financial Terms - HAPO Pharmaceutical will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms are consistent with the financial framework agreed upon in March 2025 [1]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has announced an update to its global strategic collaboration with AstraZeneca, focusing on the discovery and development of next-generation biotherapies, including antibody-drug conjugates (ADCs) and T-cell engagers (TCEs) [1] Group 1: Collaboration Details - The collaboration will see AstraZeneca nominate R&D projects to Heptagon Pharmaceuticals annually over the next four years, highlighting the deepening partnership [1] - Heptagon Pharmaceuticals will be eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of licensed projects [1] - The economic terms of this collaboration align with the financial framework established in March 2025 [1] Group 2: Market Reaction - Heptagon Pharmaceuticals' stock rose nearly 4% in the afternoon session, with a current increase of 3.15%, trading at HKD 13.76, and a transaction volume of HKD 33.4244 million [1]

Core Viewpoint - Heptagon Pharmaceuticals (02142) has seen a stock increase of over 4%, currently trading at 14.22 HKD, with a transaction volume of 27.84 million HKD, following the announcement of an updated global strategic collaboration with AstraZeneca established in March 2025 [1] Group 1: Collaboration Details - The collaboration aims to jointly discover and develop next-generation biotherapies, including antibody-drug conjugates (ADC) and T-cell engagers (TCE) [1] - AstraZeneca will nominate R&D projects annually for the next four years, highlighting the deepening partnership between the two companies [1] - Heptagon Pharmaceuticals is eligible to receive option fees, exercise fees, development and commercial milestone payments, as well as tiered royalties based on future net sales of the licensed projects, consistent with the financial framework established in March 2025 [1]